Obesity - Pipeline Review, H2 2014

Date: September 30, 2014
Pages: 501
Price:
US$ 2,000.00 US$ 1,800.00
Offer valid until December 31, 2014!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: O5F2BC0D9C1EN
Leaflet:

Download PDF Leaflet

Summary

Global Markets Direct’s, ‘Obesity - Pipeline Review, H2 2014’, provides an overview of the Obesity’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Obesity, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Obesity and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • The report provides a snapshot of the global therapeutic landscape of Obesity
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Obesity and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Obesity products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Obesity pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Obesity
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Obesity pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Obesity Overview
Therapeutics Development
Obesity - Therapeutics under Development by Companies
Obesity - Therapeutics under Investigation by Universities/Institutes
Obesity - Pipeline Products Glance
Obesity - Products under Development by Companies
Obesity - Products under Investigation by Universities/Institutes
Obesity - Companies Involved in Therapeutics Development
Obesity - Therapeutics Assessment
Drug Profiles
Obesity - Recent Pipeline Updates
Obesity - Dormant Projects
Obesity - Discontinued Products
Obesity - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Obesity, H2 2014
Number of Products under Development for Obesity - Comparative Analysis, H2 2014
Number of Products under Development by Companies, H2 2014
Number of Products under Development by Companies, H2 2014 (Contd..1)
Number of Products under Development by Companies, H2 2014 (Contd..2)
Number of Products under Development by Companies, H2 2014 (Contd..3)
Number of Products under Development by Companies, H2 2014 (Contd..4)
Number of Products under Development by Companies, H2 2014 (Contd..5)
Number of Products under Development by Companies, H2 2014 (Contd..6)
Number of Products under Development by Companies, H2 2014 (Contd..7)
Number of Products under Investigation by Universities/Institutes, H2 2014
Number of Products under Investigation by Universities/Institutes, H2 2014 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H2 2014 (Contd..2)
Comparative Analysis by Late Stage Development, H2 2014
Comparative Analysis by Clinical Stage Development, H2 2014
Comparative Analysis by Early Stage Development, H2 2014
Products under Development by Companies, H2 2014
Products under Development by Companies, H2 2014 (Contd..1)
Products under Development by Companies, H2 2014 (Contd..2)
Products under Development by Companies, H2 2014 (Contd..3)
Products under Development by Companies, H2 2014 (Contd..4)
Products under Development by Companies, H2 2014 (Contd..5)
Products under Development by Companies, H2 2014 (Contd..6)
Products under Development by Companies, H2 2014 (Contd..7)
Products under Development by Companies, H2 2014 (Contd..8)
Products under Development by Companies, H2 2014 (Contd..9)
Products under Development by Companies, H2 2014 (Contd..10)
Products under Development by Companies, H2 2014 (Contd..11)
Products under Investigation by Universities/Institutes, H2 2014
Products under Investigation by Universities/Institutes, H2 2014 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2014 (Contd..2)
Products under Investigation by Universities/Institutes, H2 2014 (Contd..3)
Obesity - Pipeline by Bristol-Myers Squibb Company, H2 2014
Obesity - Pipeline by Johnson & Johnson, H2 2014
Obesity - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014
Obesity - Pipeline by Shionogi & Co., Ltd., H2 2014
Obesity - Pipeline by Amgen Inc., H2 2014
Obesity - Pipeline by Sanofi, H2 2014
Obesity - Pipeline by AstraZeneca PLC, H2 2014
Obesity - Pipeline by Eli Lilly and Company, H2 2014
Obesity - Pipeline by Athersys, Inc., H2 2014
Obesity - Pipeline by GlaxoSmithKline plc, H2 2014
Obesity - Pipeline by Isis Pharmaceuticals, Inc., H2 2014
Obesity - Pipeline by Merck & Co., Inc., H2 2014
Obesity - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2014
Obesity - Pipeline by Euroscreen S.A., H2 2014
Obesity - Pipeline by Novo Nordisk A/S, H2 2014
Obesity - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014
Obesity - Pipeline by Plexxikon Inc., H2 2014
Obesity - Pipeline by Ipsen S.A., H2 2014
Obesity - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2014
Obesity - Pipeline by GTx, Inc., H2 2014
Obesity - Pipeline by Kissei Pharmaceutical Co., Ltd., H2 2014
Obesity - Pipeline by LEO Pharma A/S, H2 2014
Obesity - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2014
Obesity - Pipeline by Pfizer Inc., H2 2014
Obesity - Pipeline by Vivus, Inc., H2 2014
Obesity - Pipeline by Zydus Cadila Healthcare Limited, H2 2014
Obesity - Pipeline by OPKO Health, Inc., H2 2014
Obesity - Pipeline by Arrowhead Research Corporation, H2 2014
Obesity - Pipeline by Calzada Limited, H2 2014
Obesity - Pipeline by Orchid Chemicals & Pharmaceuticals Ltd, H2 2014
Obesity - Pipeline by Arena Pharmaceuticals, Inc., H2 2014
Obesity - Pipeline by Shanghai Pharmaceutical Co., Ltd., H2 2014
Obesity - Pipeline by WhanIn Pharmaceutical Co., Ltd., H2 2014
Obesity - Pipeline by Xenetic Biosciences plc, H2 2014
Obesity - Pipeline by Handok Inc., H2 2014
Obesity - Pipeline by LG Life Sciences, Ltd., H2 2014
Obesity - Pipeline by Transition Therapeutics Inc., H2 2014
Obesity - Pipeline by Suven Life Sciences Ltd., H2 2014
Obesity - Pipeline by Galapagos NV, H2 2014
Obesity - Pipeline by CrystalGenomics, Inc., H2 2014
Obesity - Pipeline by Orexigen Therapeutics, Inc., H2 2014
Obesity - Pipeline by Digna Biotech, S.L., H2 2014
Obesity - Pipeline by Advinus Therapeutics Ltd., H2 2014
Obesity - Pipeline by Jenrin Discovery, Inc., H2 2014
Obesity - Pipeline by Upsher-Smith Laboratories, Inc., H2 2014
Obesity - Pipeline by ObeTherapy Biotechnology, H2 2014
Obesity - Pipeline by Helsinn Healthcare S.A., H2 2014
Obesity - Pipeline by AngioChem Inc., H2 2014
Obesity - Pipeline by Kedem Pharmaceuticals Inc., H2 2014
Obesity - Pipeline by Zafgen Inc., H2 2014
Obesity - Pipeline by Ambrx, Inc., H2 2014
Obesity - Pipeline by Braasch Biotech LLC, H2 2014
Obesity - Pipeline by Zealand Pharma A/S, H2 2014
Obesity - Pipeline by Intarcia Therapeutics, Inc., H2 2014
Obesity - Pipeline by Versartis, Inc., H2 2014
Obesity - Pipeline by Kainos Medicine, Inc., H2 2014
Obesity - Pipeline by Nordic Bioscience a/s, H2 2014
Obesity - Pipeline by Avaxia Biologics, Inc., H2 2014
Obesity - Pipeline by Omeros Corporation, H2 2014
Obesity - Pipeline by Aegis Therapeutics, LLC, H2 2014
Obesity - Pipeline by Bridge Bioresearch Plc, H2 2014
Obesity - Pipeline by Targacept, Inc., H2 2014
Obesity - Pipeline by Molecular Design International, Inc., H2 2014
Obesity - Pipeline by N-Gene Research Laboratories, Inc., H2 2014
Obesity - Pipeline by Seek, H2 2014
Obesity - Pipeline by Vitae Pharmaceuticals, Inc., H2 2014
Obesity - Pipeline by Galenea Corp., H2 2014
Obesity - Pipeline by Verva Pharmaceuticals Limited, H2 2014
Obesity - Pipeline by Regulus Therapeutics Inc., H2 2014
Obesity - Pipeline by Esperion Therapeutics, Inc., H2 2014
Obesity - Pipeline by Sorrento Therapeutics, Inc., H2 2014
Obesity - Pipeline by NGM Biopharmaceuticals, Inc., H2 2014
Obesity - Pipeline by Alize Pharma SAS, H2 2014
Obesity - Pipeline by DiscoveryBiomed, Inc., H2 2014
Obesity - Pipeline by Sirona Biochem Corp, H2 2014
Obesity - Pipeline by Vicore Pharma AB, H2 2014
Obesity - Pipeline by Carmot Therapeutics, Inc., H2 2014
Obesity - Pipeline by Reviva Pharmaceuticals Inc., H2 2014
Obesity - Pipeline by PharmaIN Corporation, H2 2014
Obesity - Pipeline by Rhythm Pharmaceuticals, H2 2014
Obesity - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2014
Obesity - Pipeline by X-BODY BioSciences, Inc., H2 2014
Obesity - Pipeline by Lead Discovery Center GmbH, H2 2014
Obesity - Pipeline by AtheroNova Inc., H2 2014
Obesity - Pipeline by P2D Bioscience, H2 2014
Obesity - Pipeline by High Point Pharmaceuticals, LLC, H2 2014
Obesity - Pipeline by Arrien Pharmaceuticals, LLC, H2 2014
Obesity - Pipeline by Chronos Therapeutics Limited, H2 2014
Obesity - Pipeline by Kadmon Corporation, LLC, H2 2014
Obesity - Pipeline by nLife Therapeutics, S.L., H2 2014
Obesity - Pipeline by Orbis Biosciences, Inc., H2 2014
Obesity - Pipeline by XL-protein GmbH, H2 2014
Obesity - Pipeline by Akron Molecules AG, H2 2014
Assessment by Monotherapy Products, H2 2014
Assessment by Combination Products, H2 2014
Number of Products by Stage and Target, H2 2014
Number of Products by Stage and Mechanism of Action, H2 2014
Number of Products by Stage and Route of Administration, H2 2014
Number of Products by Stage and Molecule Type, H2 2014
Obesity Therapeutics - Recent Pipeline Updates, H2 2014
Obesity - Dormant Projects, H2 2014
Obesity - Discontinued Products, H2 2014

LIST OF FIGURES

Number of Products under Development for Obesity, H2 2014
Number of Products under Development for Obesity - Comparative Analysis, H2 2014
Number of Products under Development by Companies, H2 2014
Number of Products under Investigation by Universities/Institutes, H2 2014
Comparative Analysis by Late Stage Development, H2 2014
Comparative Analysis by Clinical Stage Development, H2 2014
Comparative Analysis by Early Stage Products, H2 2014
Assessment by Monotherapy Products, H2 2014
Assessment by Combination Products, H2 2014
Number of Products by Top 10 Target, H2 2014
Number of Products by Stage and Top 10 Target, H2 2014
Number of Products by Top 10 Mechanism of Action, H2 2014
Number of Products by Stage and Top 10 Mechanism of Action, H2 2014
Number of Products by Top 10 Route of Administration, H2 2014
Number of Products by Stage and Top 10 Route of Administration, H2 2014
Number of Products by Top 10 Molecule Type, H2 2014
Number of Products by Stage and Top 10 Molecule Type, H2 2014
Obesity - Pipeline Review, Q1 2011 US$ 450.00 Feb, 2011 · 107 pages
VIVUS, Inc. - Product Pipeline Review - Q4 2010 US$ 450.00 Dec, 2010 · 69 pages
Athersys, Inc. - Product Pipeline Review - Q4 2010 US$ 450.00 Nov, 2010 · 51 pages

Ask Your Question

Obesity - Pipeline Review, H2 2014
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: